Transforming Inflammation & Oxidative Stress Therapies
rngen is pioneering a new class of first-in-class drug candidates called Systems Chemico-Pharmacology Drugs (SCPDs) to treat both acute injuries and chronic diseases by precisely modulating inflammatory and oxidative stress pathways.
What Makes SCPDs Unique?
- Targeted Activation – SCPDs are chemically activated within the disease environment, ensuring localized action.
- Redox Enzyme-Guided Specificity – The drug anchors within an enzyme active site, triggering a cascade that modifies key inflammatory pathways.
- Multi-Step Modulation – After initial activation, the drug undergoes a secondary transformation, interacting with additional molecular targets to enhance therapeutic effects.
- Regiochemical Precision – SCPDs confer specificity through carefully designed regiochemical interactions, minimizing off-target effects.
Lead Candidate: KYC
rngen’s lead compound, N-acetyl lysyltyrosylcysteine amide (KYC), is an end-capped tripeptide designed to combat inflammation and oxidative stress-driven acute and chronic damage.
Mechanism of Action
- Targets Myeloperoxidase (MPO) to block hypochlorous acid (HOCl), a potent inflammatory and oxidative stress agent.
- Undergoes a controlled redox transformation, generating a thiyl radical that modulates inflammatory mediators.
- Reduces recruitment of harmful immune cells while enhancing pro-repair immune responses—promoting tissue regeneration and limiting secondary damage.
Clinical Potential
- Validated in preclinical studies for multiple inflammatory and oxidative stress-related conditions.
- Versatile administration routes under development for optimized PK/PD profiles.
- Pipeline Expansion: rngen is expanding its SCPD library to address diseases ranging from neuroinflammation and cardiovascular disease to tissue repair and immune modulation.
Cinical Impact
Each SCPD is tailored for specific indications and delivery methods, maximizing clinical impact.
rngen SCPD Compound Library
rngen’s SCPD platform is designed to generate a new class of therapeutics targeting inflammation and oxidative stress through precision redox modulation and multi-pathway engagement. This compound library is built around distinct functional attributes, enabling strategic targeting of key oxidative and inflammatory pathways and different routes of administration.
| Category | Compounds | Core SCPD Mechanism & Potential Applications |
|---|---|---|
| Hematologic & Pulmonary Inflammation Modulators | RNG-001 (KYC) | Targets MPO-driven oxidative stress to reduce inflammation and vascular damage in Bronchopulmonary Dysplasia (BPD) and Sickle Cell Disease (SCD). |
| Lung & Circulatory System Redox Regulators | RNG-003, RNG-006, RNG-009, RNG-011 | Modulates oxidative stress and inflammatory cascades in pulmonary and cardiovascular conditions, including vascular dysfunction, lung injury, and fibrosis-related diseases. |
| Neuroinflammation & CNS Redox Modulators | RNG-021, RNG-025, RNG-031 | Designed to cross the blood-brain barrier and regulate oxidative and inflammatory damage in neurodegenerative diseases, traumatic brain injury (TBI), and other CNS disorders. |
| Broad-Spectrum Peptoid-Based SCPD | RNG-050 | Engineered as a high-stability, multifunctional peptoid, applicable to multiple disease conditions involving systemic oxidative stress and inflammation. |
rngen Drug Compound Library DDD Process
Lead Compound Screening
- RNG-009
- RNG-021
- RNG-025
- RNG-031
- RNG-050
Lead Optimization
- RNG-003
- RNG-006
- RNG-011
Preclinical
- RNG-001
Clinical
Pipeline Evolution & Future Applications
rngen’s Compound Library represents an adaptive drug discovery approach, where each candidate undergoes rigorous molecular and preclinical evaluation to refine its ideal clinical use case, delivery method, and pharmacokinetics.
We are actively expanding and optimizing our SCPD portfolio to address a range of inflammatory and oxidative stress-related conditions, ensuring that each compound is aligned with emerging clinical needs and translational opportunities.
By leveraging systems chemistry, targeted redox modulation, and multi-tiered therapeutic engagement, rngen is shaping the next generation of inflammation and oxidative stress therapies—with the flexibility to tackle acute, chronic, and regenerative medicine applications.
Rationale for Investors & Pharma Partners
- Disruptive Platform: SCPDs offer a novel multi-target approach for inflammation and oxidative stress-driven diseases.
- Broad Market Potential: Addressing unmet needs in neurology, cardiovascular, autoimmune, and rare diseases.
- De-risked by Preclinical Data: Demonstrated efficacy in multiple models of acute and chronic disease.
- Scalability & Partnering Opportunities: Proprietary pipeline with multiple indications and regulatory pathways for licensing, co-development, or acquisition.
rngen is actively seeking strategic investors and pharma partners to advance SCPD development through IND and clinical trials.